CompletedPhase 3NCT03814187

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Studying Rare hypercholesterolemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Novartis Pharmaceuticals
Principal Investigator
Scott Wright, MD
Mayo Clinic
Intervention
Inclisiran Sodium(drug)
Enrollment
3275 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2023

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03814187 on ClinicalTrials.gov

Other trials for Rare hypercholesterolemia

Additional recruiting or active studies for the same condition.

See all trials for Rare hypercholesterolemia →

← Back to all trials